A double-blind, placebo-controlled study of HP-5070 in patients with primary hyperhidrosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200142

Enrollment

260

Registered

2020-10-09

Start date

2020-10-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary local hyperhidrosis

Interventions

Transdermal application of HP-5070 (oxybutynin hydrochloride) or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Japanese patients aged 12 years or older - Patients with a diagnosis of primary local hyperhidrosis - Patients with involvement of palmar sites

Exclusion criteria

Exclusion criteria: - Patients with secondary hyperhidrosis - Patients with heavy sweating due to climacteric disturbance - Patients who have undergone surgery for hyperhidrosis (sympathectomy, nerve block, laser surgery, etc.)

Design outcomes

Primary

Measure	Time frame
The proportion of responders with the defined volume of sweat	—

Secondary

Measure	Time frame
HDSS (Hyperhidrosis Disease Severity Scale) DLQI (Dermatology Life Quality Index) score Adverse events	—

Contacts

Public ContactOffice Customer Service

Hisamitsu Pharmaceutical Co., Inc.

sodanshitsu@hisamitsu.co.jp+81-120-381332

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026